GLAND

📅 Upcoming

🕒 Recent(90d)

News

• Why OMass’ $310M series C marks ‘fantastic milestone’ on journey to become ‘Britain’s Big Biotech’
  When Fierce last caught up with OMass Therapeutics’ CEO Ros Deegan, it was hard not to be impressed by the company’s ambition.
  fiercebiotech · 20d ago
• Lilly adds to immune drug pipeline with $2.9B Merida buyout
  The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.
  biopharma_dive · 2mo ago
• Scientists deploy Merck’s Ebola vaccine in DRC
  Prostate cancer therapy, Meta glasses in hospital settings, and more health news from Morning Rounds
  stat · 2mo ago
• Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?
  Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery or radiation.
  stat · 2mo ago
• MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them
  Pre-biopsy MRI is standard outside the U.S., but the latest data show such scans were done in only about a third of U.S. prostate cancer cases in 2022.
  stat · 3mo ago
• BridgeBio gets funding for drug launch; United buys into cell therapy
  Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
  biopharma_dive · 4mo ago
• Ethyreal starts up with $101M and takes aim at a pair of immune diseases
  The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
  biopharma_dive · 4mo ago